Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Gemcitabine/Platinum in Advanced NSCLC
NCT00112346Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2005
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of KL-140 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Tumor Response per Treatment Arm. Started Jan 2005; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00112346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112346.